Henry Flanner

Mr. Flanner has over 25 years of experience in the development of biopharmaceutical products in emerging pharmaceutical companies. He joined Veralox in 2021 bringing expertise in chemistry, manufacturing, and controls (CMC), as well as broader pharmaceutical development experience relating CMC to non-clinical toxicology, ADME and pharmacokinetics. Prior to joining Veralox, Mr. Flanner was Vice President of Technical Operations and Non-clinical Development at GlycoMimetics, Inc., Senior Director of Pharmaceutical Research at MiddleBrook Pharmaceuticals, and Director of Drug Delivery Sciences at Shire Laboratories. He holds over twenty formulation patents. Mr. Flanner co-developed the in vitro dissolution profile comparison metrics, ƒ1 and ƒ2, which are cited in multiple international regulatory guidance documents as in vitro justification for certain CMC changes in lieu of clinical bioequivalence studies. He received a B.S. in Chemical Engineering from the University of South Carolina, and a Master of Chemical Engineering from Johns Hopkins University.